Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology to Participate in Upcoming Investor Conference
07:30am, Wednesday, 24'th Sep 2025
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy
11:03am, Friday, 19'th Sep 2025
Kura Oncology is rated Buy, driven by a strong cash position, strategic Kyowa Kirin partnership, and a robust, diversified pipeline. KURA's lead asset, Ziftomenib, targets AML and awaits a pivotal FDA
Kura Oncology, Inc. - Special Call
10:53pm, Tuesday, 16'th Sep 2025
Kura Oncology, Inc. - Special Call Company Participants Troy Wilson - Chairman, CEO & President Francis Burrows - Chief Scientific Officer Mollie Leoni - Chief Medical Officer Conference Call Particip
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)
Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
04:44pm, Wednesday, 10'th Sep 2025
Kura Oncology, Inc. (NASDAQ:KURA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Troy Wilson - Chairman, CEO & President Brian Powl - Chie
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 05'th Sep 2025
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicin
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
08:02am, Wednesday, 03'rd Sep 2025
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies
Kura Oncology to Participate in Three Upcoming Investor Conferences
07:30am, Thursday, 28'th Aug 2025
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript
10:46pm, Saturday, 09'th Aug 2025
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian T. Powl - Chief Commercial Officer Greg Mann - Corporate Participant Mollie Leo
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
07:16pm, Thursday, 07'th Aug 2025
Kura Oncology (KURA) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of $0.15. This compares to a loss of $0.59 per share a year ago.
Kura (KURA) Revenue Drops 61%
05:07pm, Thursday, 07'th Aug 2025
Kura (KURA) Revenue Drops 61%
Kura Oncology Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Full
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Monday, 04'th Aug 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology to Report Second Quarter 2025 Financial Results
07:30am, Thursday, 31'st Jul 2025
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Thursday, 03'rd Jul 2025
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
